Ambrisentan 304 PROTAC AR Degrader-4 comprises a

PROTAC AR Degrader-4 comprises a cIAP1 ligand binding group

J Steroid Biochem Mol Biol

3-dimethyl-1-oxobutan-2-yl)amino)-4-oxobutanoic acid

Varespladib reduces atherosclerosis and aneurysm formation in ApoE-/- mice and in guinea pigs

951441-04-6

Ambrisentan 304 PROTAC AR Degrader-4 comprises aAmbrisentan, also known as BSF 208075 and LU 208075, is a drug indicated for use in the treatment of pulmonary hypertension. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan significantly improved exercise capacity (6 minute walk distance) compared with placebo in two double blind, multicenter trials (ARIES 1 and ARIES 2). Ambrisentan was approved by